Profile data is unavailable for this security.
About the company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.
- Revenue in USD (TTM)20.04m
- Net income in USD-126.07m
- Incorporated2015
- Employees145.00
- LocationC4 Therapeutics Inc490 Arsenal Way, Suite 120WATERTOWN 02472United StatesUSA
- Phone+1 (617) 231-0700
- Fax+1 (302) 655-5049
- Websitehttps://c4therapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cerus Corp | 186.80m | -37.49m | 364.23m | 288.00 | -- | 6.78 | -- | 1.95 | -0.2086 | -0.2086 | 1.04 | 0.2905 | 0.8984 | 2.03 | 5.34 | 648,600.70 | -18.11 | -25.99 | -32.81 | -40.62 | 62.54 | 61.90 | -20.15 | -35.81 | 1.55 | -2.91 | 0.5989 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| Tenaya Therapeutics Inc | 0.00 | -124.58m | 365.89m | 140.00 | -- | 2.31 | -- | -- | -1.65 | -1.65 | 0.00 | 2.01 | 0.00 | -- | -- | 0.00 | -57.91 | -- | -63.59 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| MeiraGTx Holdings PLC | 11.38m | -74.11m | 367.19m | 402.00 | -- | 3.02 | -- | 32.27 | -1.27 | -1.27 | 0.1887 | 1.89 | 0.0381 | -- | 0.4821 | 27,159.90 | -24.81 | -26.40 | -31.62 | -32.66 | -- | -- | -651.19 | -420.70 | -- | -27.54 | 0.3729 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Verrica Pharmaceuticals Inc | 8.91m | -80.74m | 367.78m | 100.00 | -- | 243.89 | -- | 41.26 | -1.75 | -1.75 | 0.1929 | 0.0356 | 0.1321 | -- | 2.33 | 89,130.00 | -119.66 | -55.75 | -142.98 | -78.33 | 79.63 | -- | -905.83 | -754.94 | 3.04 | -21.71 | 0.9678 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Nautilus Biotechnology Inc | 0.00 | -67.44m | 369.53m | 163.00 | -- | 1.48 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -19.06m | 371.36m | 10.00 | -- | 295.61 | -- | -- | -0.9149 | -0.9149 | 0.00 | 0.0384 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -60.47 | 0.1012 | -- | -- | -- | -272.15 | -- | -- | -- |
| Shattuck Labs Inc | 2.72m | -85.08m | 376.37m | 75.00 | -- | 2.92 | -- | 138.62 | -1.93 | -1.93 | 0.0608 | 2.71 | 0.0168 | -- | -- | 36,200.00 | -52.52 | -29.14 | -57.94 | -32.42 | -- | -- | -3,133.63 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Anika Therapeutics Inc | 169.26m | -76.83m | 376.64m | 357.00 | -- | 1.81 | -- | 2.23 | -5.24 | -5.24 | 11.54 | 14.07 | 0.5616 | 1.42 | 5.40 | 474,120.40 | -25.49 | -5.41 | -28.16 | -5.87 | 61.96 | 60.70 | -45.39 | -12.60 | 3.85 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -91.06m | 381.58m | 66.00 | -- | 1.61 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
| Anavex Life Sciences Corp | 0.00 | -40.59m | 385.12m | 40.00 | -- | 2.82 | -- | -- | -0.4962 | -0.4962 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -26.73 | -40.04 | -28.98 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Tourmaline Bio Inc | 0.00 | -32.94m | 385.72m | 44.00 | -- | 1.09 | -- | -- | -5.35 | -5.35 | 0.00 | 13.81 | 0.00 | -- | -- | 0.00 | -12.39 | -- | -12.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| C4 Therapeutics Inc | 20.04m | -126.07m | 390.82m | 145.00 | -- | 1.51 | -- | 19.51 | -2.37 | -2.37 | 0.3677 | 3.76 | 0.0504 | -- | 2.84 | 138,179.30 | -31.74 | -25.91 | -36.02 | -29.45 | -- | -- | -629.24 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| ADC Therapeutics SA | 68.62m | -227.23m | 394.38m | 273.00 | -- | -- | -- | 5.75 | -2.77 | -2.77 | 0.8368 | -2.35 | 0.1769 | 0.2683 | 2.91 | 251,351.60 | -56.99 | -48.41 | -69.99 | -55.63 | 93.30 | -- | -322.09 | -308.62 | 4.35 | -4.14 | 1.85 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Replimune Group Inc | 0.00 | -215.79m | 395.34m | 331.00 | -- | 1.06 | -- | -- | -3.24 | -3.24 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -38.05 | -29.08 | -40.71 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1593 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Annexon Inc | 0.00 | -120.74m | 400.15m | 70.00 | -- | 1.49 | -- | -- | -1.46 | -1.46 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -42.15 | -44.06 | -44.99 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Contineum Therapeutics Inc | 50.00m | 22.72m | 405.51m | 31.00 | 17.14 | -- | 17.66 | 8.11 | 0.9041 | 0.9041 | 1.99 | 4.96 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 45.44 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
Data as of May 20 2024. Currency figures normalised to C4 Therapeutics Inc's reporting currency: US Dollar USD
50.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 7.15m | 10.43% |
| RA Capital Management LPas of 31 Mar 2024 | 4.88m | 7.11% |
| Wasatch Advisors, Inc.as of 31 Mar 2024 | 4.33m | 6.31% |
| Lynx1 Capital Management LPas of 31 Mar 2024 | 3.63m | 5.30% |
| Commodore Capital LPas of 31 Mar 2024 | 3.41m | 4.97% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.90m | 4.23% |
| Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 2.46m | 3.59% |
| Balyasny Asset Management LPas of 31 Mar 2024 | 2.44m | 3.55% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.07m | 3.02% |
| BofA Securities, Inc.as of 31 Mar 2024 | 1.55m | 2.26% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
